<?xml version="1.0" encoding="UTF-8"?>
  	<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9"><url>
      <loc>https://www.hcplive.com/view/targeting-the-disease-mechanism-in-pfic-with-hisamitsu-hayashi-phd</loc><lastmod>2026-10-06T20:00:48.599Z</lastmod><news:news><news:publication_date>2026-10-06T20:00:48.599Z</news:publication_date>
        <news:title><![CDATA[Targeting the Disease Mechanism in PFIC, With Hisamitsu Hayashi, PhD]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/asthma-exacerbations-biologics-phenotyping-schleich</loc><lastmod>2026-10-06T19:14:26.296Z</lastmod><news:news><news:publication_date>2026-10-06T19:14:26.296Z</news:publication_date>
        <news:title><![CDATA[Residual Asthma Exacerbations on Biologics Vary by Mechanism]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/addressing-the-lingering-challenge-of-hypoglycemia-in-t1d-with-john-buse-md-phd</loc><lastmod>2026-10-06T17:30:00Z</lastmod><news:news><news:publication_date>2026-10-06T17:30:00Z</news:publication_date>
        <news:title><![CDATA[Addressing the Lingering Challenge of Hypoglycemia in T1D, With John Buse, MD, PhD]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/3-hematology-headlines-you-missed-in-september-2026</loc><lastmod>2026-10-06T16:48:51.025Z</lastmod><news:news><news:publication_date>2026-10-06T16:48:51.025Z</news:publication_date>
        <news:title><![CDATA[3 Hematology Headlines You Missed in September 2026]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/acg-guideline-sets-18-preventive-care-recommendations-for-cirrhosis</loc><lastmod>2026-10-06T16:00:00.000Z</lastmod><news:news><news:publication_date>2026-10-06T16:00:00Z</news:publication_date>
        <news:title><![CDATA[ACG Guideline Sets 18 Preventive Care Recommendations for Cirrhosis]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/relieve-ad-peds-dupilumab-sustains-adolescent-atopic-dermatitis-control-1-year</loc><lastmod>2026-10-06T15:40:46.460Z</lastmod><news:news><news:publication_date>2026-10-06T15:40:46.460Z</news:publication_date>
        <news:title><![CDATA[RELIEVE-AD-PEDs: Dupilumab Sustains Adolescent Atopic Dermatitis Control at 1 Year]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/delayed-penicillin-rash-autoimmunity-kristal</loc><lastmod>2026-10-06T15:27:25.353Z</lastmod><news:news><news:publication_date>2026-10-06T15:27:25.353Z</news:publication_date>
        <news:title><![CDATA[Delayed Penicillin Rash and Later Autoimmunity, With Eyal Kristal, MD]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/designing-the-next-fibrillary-gn-trial-b-cell-agents-and-t-cell-engagers</loc><lastmod>2026-10-06T14:36:10.053Z</lastmod><news:news><news:publication_date>2026-10-06T14:36:10.053Z</news:publication_date>
        <news:title><![CDATA[Designing the Next Fibrillary GN Trial: B-Cell Agents and T-Cell Engagers]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/managing-non-responders-in-glomerular-disease-proteinuria-targets-by-disease</loc><lastmod>2026-10-06T14:36:08.639Z</lastmod><news:news><news:publication_date>2026-10-06T14:36:08.639Z</news:publication_date>
        <news:title><![CDATA[Managing Non-Responders in Glomerular Disease: Proteinuria Targets by Disease]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/fibrillary-gn-cardiovascular-protection-and-recurrence-after-kidney-transplant</loc><lastmod>2026-10-06T14:36:06.890Z</lastmod><news:news><news:publication_date>2026-10-06T14:36:06.890Z</news:publication_date>
        <news:title><![CDATA[Fibrillary GN: Cardiovascular Protection and Recurrence After Kidney Transplant]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/conservative-therapy-in-fibrillary-gn-a-four-drug-kidney-protective-approach</loc><lastmod>2026-10-06T14:36:05.207Z</lastmod><news:news><news:publication_date>2026-10-06T14:36:05.207Z</news:publication_date>
        <news:title><![CDATA[Conservative Therapy in Fibrillary GN: A Four-Drug Kidney-Protective Approach]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/immunosuppression-in-fibrillary-gn-early-biopsy-and-histology-guided-treatment</loc><lastmod>2026-10-06T14:36:03.698Z</lastmod><news:news><news:publication_date>2026-10-06T14:36:03.698Z</news:publication_date>
        <news:title><![CDATA[Immunosuppression in Fibrillary GN: Early Biopsy and Histology-Guided Treatment]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/second-line-therapy-in-fibrillary-gn-secondary-causes-and-rituximab-data</loc><lastmod>2026-10-06T14:36:01.724Z</lastmod><news:news><news:publication_date>2026-10-06T14:36:01.724Z</news:publication_date>
        <news:title><![CDATA[Second-Line Therapy in Fibrillary GN: Secondary Causes and Rituximab Data]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/reason-leaving-hae-attacks-untreated-survey</loc><lastmod>2026-10-06T12:00:00Z</lastmod><news:news><news:publication_date>2026-10-06T12:00:00Z</news:publication_date>
        <news:title><![CDATA[Top Reason for Leaving HAE Attacks Untreated, Survey Finds]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/the-benefits-and-limits-of-enlicitide-with-ninel-hovnanians-md</loc><lastmod>2026-10-05T21:00:00Z</lastmod><news:news><news:publication_date>2026-10-05T21:00:00Z</news:publication_date>
        <news:title><![CDATA[The Benefits and Limits of Enlicitide, With Ninel Hovnanians, MD]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/6-nephrology-headlines-you-missed-in-september-2026</loc><lastmod>2026-10-05T20:00:00Z</lastmod><news:news><news:publication_date>2026-10-05T20:00:00Z</news:publication_date>
        <news:title><![CDATA[6 Nephrology Headlines You Missed in September 2026]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/5-gastroenterology-headlines-you-missed-in-september-2026</loc><lastmod>2026-10-05T19:00:00Z</lastmod><news:news><news:publication_date>2026-10-05T19:00:00Z</news:publication_date>
        <news:title><![CDATA[5 Gastroenterology Headlines You Missed in September 2026]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/eadv-2026-tnf-ox40l-cluster-hs-draining-tunnels</loc><lastmod>2026-10-05T17:33:35.442Z</lastmod><news:news><news:publication_date>2026-10-05T17:33:35.442Z</news:publication_date>
        <news:title><![CDATA[EADV 2026: TNFα, OX40L Cluster at HS Draining Tunnels]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/q3-2026-recap-psychiatry-news-updates</loc><lastmod>2026-10-05T17:25:00Z</lastmod><news:news><news:publication_date>2026-10-05T17:25:00Z</news:publication_date>
        <news:title><![CDATA[Q3 2026 Recap: Psychiatry News and Updates]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/q-a-dupilumab-improves-quality-life-omalizumab-naive-csu</loc><lastmod>2026-10-05T16:11:01.950Z</lastmod><news:news><news:publication_date>2026-10-05T16:11:01.950Z</news:publication_date>
        <news:title><![CDATA[Q&A: Dupilumab Improves Quality of Life in Omalizumab-Naive CSU]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/fda-updates-sotatercept-label-ers-releases-pah-guidelines-based-on-hyperion-data</loc><lastmod>2026-10-05T16:00:00Z</lastmod><news:news><news:publication_date>2026-10-05T16:00:00Z</news:publication_date>
        <news:title><![CDATA[FDA Updates Sotatercept Label, ERS Releases PAH Guidelines to Include HYPERION Data]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/ritlecitinib-stabilizes-vitiligo-tranquillo-trial-iltefat-hamzavi-md</loc><lastmod>2026-10-05T15:01:43.671Z</lastmod><news:news><news:publication_date>2026-10-05T15:01:43.671Z</news:publication_date>
        <news:title><![CDATA[Ritlecitinib Stabilizes Vitiligo in Tranquillo Trial, With Iltefat Hamzavi, MD]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/5-hepatology-headlines-missed-september-2026</loc><lastmod>2026-10-05T13:59:00Z</lastmod><news:news><news:publication_date>2026-10-05T13:59:00Z</news:publication_date>
        <news:title><![CDATA[5 Hepatology Headlines You Missed in September 2026]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/strategies-to-improve-treatment-adherence-in-eoe-care</loc><lastmod>2026-10-05T12:05:00Z</lastmod><news:news><news:publication_date>2026-10-05T12:05:00Z</news:publication_date>
        <news:title><![CDATA[Strategies to Improve Treatment Adherence in EoE Care]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/adjusting-treatment-and-quality-of-life-in-eoe</loc><lastmod>2026-10-05T12:00:00Z</lastmod><news:news><news:publication_date>2026-10-05T12:00:00Z</news:publication_date>
        <news:title><![CDATA[Adjusting Treatment and Quality of Life in EoE]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/injectable-to-oral-optimal-durable-clearance-il-23</loc><lastmod>2026-10-05T11:30:10.903Z</lastmod><news:news><news:publication_date>2026-10-05T11:30:10.903Z</news:publication_date>
        <news:title><![CDATA[From Injectable to Oral: Optimal Durable Clearance Across the IL-23 Class]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/advances-treating-high-impact-psoriasis-eadv-2026</loc><lastmod>2026-10-05T10:19:41.080Z</lastmod><news:news><news:publication_date>2026-10-05T10:19:41.080Z</news:publication_date>
        <news:title><![CDATA[Advances in Treating High-Impact Psoriasis from EADV 2026]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/8-endocrinology-headlines-you-missed-in-q3-2026</loc><lastmod>2026-10-04T19:00:00Z</lastmod><news:news><news:publication_date>2026-10-04T19:00:00Z</news:publication_date>
        <news:title><![CDATA[8 Endocrinology Headlines You Missed in Q3 2026]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/eadv-2026-telikibart-attains-easi-75-70-week-16-atopic-dermatitis</loc><lastmod>2026-10-03T21:09:00Z</lastmod><news:news><news:publication_date>2026-10-03T21:09:00Z</news:publication_date>
        <news:title><![CDATA[EADV 2026: Telikibart Attains EASI-75 in 70% at Week 16 in Atopic Dermatitis]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/q3-2026-recap-allergy-news-updates</loc><lastmod>2026-10-03T19:00:00Z</lastmod><news:news><news:publication_date>2026-10-03T19:00:00Z</news:publication_date>
        <news:title><![CDATA[Q3 2026 Recap: Allergy News and Updates]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/upadacitinib-tops-nemolizumab-skin-itch-targets-indirect-analysis</loc><lastmod>2026-10-03T16:01:13.246Z</lastmod><news:news><news:publication_date>2026-10-03T16:01:13.246Z</news:publication_date>
        <news:title><![CDATA[Upadacitinib Tops Nemolizumab on Skin, Itch Targets in Indirect Analysis]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/8-pulmonology-headlines-you-missed-in-q3-2026</loc><lastmod>2026-10-03T14:00:00Z</lastmod><news:news><news:publication_date>2026-10-03T14:00:00Z</news:publication_date>
        <news:title><![CDATA[8 Pulmonology Headlines You Missed in Q3 2026]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/eadv-congress-2026-day-3-recap-5-headlines-to-know</loc><lastmod>2026-10-03T09:45:57.193Z</lastmod><news:news><news:publication_date>2026-10-03T09:45:57.193Z</news:publication_date>
        <news:title><![CDATA[EADV Congress 2026: Day 3 Recap—5 Headlines to Know]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/phase-3-ritlecitinib-results-vitiligo-iltefat-hamzavi-md</loc><lastmod>2026-10-03T09:25:52.733Z</lastmod><news:news><news:publication_date>2026-10-03T09:25:52.733Z</news:publication_date>
        <news:title><![CDATA[Phase 3 Ritlecitinib Results in Vitiligo, With Iltefat Hamzavi, MD]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/8-pulmonology-headlines-you-missed-in-september-2026</loc><lastmod>2026-10-02T23:00:00Z</lastmod><news:news><news:publication_date>2026-10-02T23:00:00Z</news:publication_date>
        <news:title><![CDATA[8 Pulmonology Headlines You Missed in September 2026]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/amethyst-litifilimab-sustains-cle-gains-52-weeks-werth</loc><lastmod>2026-10-02T21:20:38.873Z</lastmod><news:news><news:publication_date>2026-10-02T21:20:38.873Z</news:publication_date>
        <news:title><![CDATA[AMETHYST: Litifilimab Sustains CLE Gains at 52 Weeks, With Victoria Werth, MD]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/9-cardiology-headlines-you-missed-in-q3-2026</loc><lastmod>2026-10-02T21:00:00Z</lastmod><news:news><news:publication_date>2026-10-02T21:00:00Z</news:publication_date>
        <news:title><![CDATA[9 Cardiology Headlines You Missed in Q3 2026]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/oxygen-stigma-mike-hess-mph</loc><lastmod>2026-10-02T20:00:00Z</lastmod><news:news><news:publication_date>2026-10-02T20:00:00Z</news:publication_date>
        <news:title><![CDATA[Why Oxygen Stigma Persists, With Mike Hess, MPH]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/the-liver-keeps-the-score-americans-are-drinking-less-but-alcohol-associated-liver-disease-may-lag</loc><lastmod>2026-10-02T19:05:44.278Z</lastmod><news:news><news:publication_date>2026-10-02T19:05:44.278Z</news:publication_date>
        <news:title><![CDATA[The Liver Keeps the Score: Americans Are Drinking Less, but Alcohol-Associated Liver Disease May Lag]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/dermatology-headlines-september-2026</loc><lastmod>2026-10-02T17:27:00Z</lastmod><news:news><news:publication_date>2026-10-02T17:27:00Z</news:publication_date>
        <news:title><![CDATA[7 Dermatology Headlines You Missed in September 2026 ]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/8-endocrinology-headlines-you-missed-in-september-2026</loc><lastmod>2026-10-02T16:52:36.788Z</lastmod><news:news><news:publication_date>2026-10-02T16:52:36.788Z</news:publication_date>
        <news:title><![CDATA[8 Endocrinology Headlines You Missed in September 2026]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/no-signal-birth-defects-dupilumab-pregnancy-registry-chambers</loc><lastmod>2026-10-02T14:25:49.003Z</lastmod><news:news><news:publication_date>2026-10-02T14:25:49.003Z</news:publication_date>
        <news:title><![CDATA[No Signal for Birth Defects in Dupilumab Pregnancy Registry, With Tina Chambers, PhD, MPH]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/5-psychiatry-headlines-missed-september-2026</loc><lastmod>2026-10-02T14:07:00Z</lastmod><news:news><news:publication_date>2026-10-02T14:07:00Z</news:publication_date>
        <news:title><![CDATA[5 Psychiatry Headlines You Missed in September 2026]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/fda-accepts-nda-for-zalunfiban-in-prehospital-stemi-treatment</loc><lastmod>2026-10-02T13:45:00Z</lastmod><news:news><news:publication_date>2026-10-02T13:45:00Z</news:publication_date>
        <news:title><![CDATA[FDA Accepts NDA for Zalunfiban in Prehospital STEMI Treatment]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/iconic-total-icotrokinra-high-impact-site-clearance-2-years</loc><lastmod>2026-10-02T12:45:00Z</lastmod><news:news><news:publication_date>2026-10-02T12:45:00Z</news:publication_date>
        <news:title><![CDATA[ICONIC-TOTAL: Icotrokinra Sustains High-Impact Site Clearance at 2 Years]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/understanding-ejection-fraction-data-from-cmi-studies-for-ohcm</loc><lastmod>2026-10-02T12:05:00Z</lastmod><news:news><news:publication_date>2026-10-02T12:05:00Z</news:publication_date>
        <news:title><![CDATA[Understanding Ejection Fraction Data from CMI Studies for oHCM]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/how-real-world-registries-inform-ohcm-management</loc><lastmod>2026-10-02T12:00:00Z</lastmod><news:news><news:publication_date>2026-10-02T12:00:00Z</news:publication_date>
        <news:title><![CDATA[How Real-World Registries inform oHCM Management]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/oral-options-tyk2-inhibitors-atopic-dermatitis-innovations-leon-kircik-md</loc><lastmod>2026-10-02T11:39:26.529Z</lastmod><news:news><news:publication_date>2026-10-02T11:39:26.529Z</news:publication_date>
        <news:title><![CDATA[Oral Options, TYK2 inhibitors, and Atopic Dermatitis Innovations, With Leon Kircik, MD]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/first-class-oral-env-294-evaluated-atopic-dermatitis-leon-kircik-md</loc><lastmod>2026-10-02T07:00:00Z</lastmod><news:news><news:publication_date>2026-10-02T07:00:00Z</news:publication_date>
        <news:title><![CDATA[First-in-Class Oral ENV-294 Evaluated in Atopic Dermatitis, With Leon Kircik, MD]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/7-cardiology-headlines-you-missed-in-september-2026</loc><lastmod>2026-10-01T23:00:00Z</lastmod><news:news><news:publication_date>2026-10-01T23:00:00Z</news:publication_date>
        <news:title><![CDATA[7 Cardiology Headlines You Missed in September 2026]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/4-allergy-headlines-missed-september-2026</loc><lastmod>2026-10-01T21:00:00Z</lastmod><news:news><news:publication_date>2026-10-01T21:00:00Z</news:publication_date>
        <news:title><![CDATA[4 Allergy Headlines You Missed in September 2026]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/synchronize-2-survodutide-outperforms-placebo-in-weight-loss-blood-sugar-control</loc><lastmod>2026-10-01T20:00:00Z</lastmod><news:news><news:publication_date>2026-10-01T20:00:00Z</news:publication_date>
        <news:title><![CDATA[SYNCHRONIZE-2: Survodutide Outperforms Placebo in Weight Loss, Blood Sugar Control]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/after-decades-of-damage-and-a-pandemic-spike-where-does-alcohol-associated-liver-disease-stand-</loc><lastmod>2026-10-01T19:00:00Z</lastmod><news:news><news:publication_date>2026-10-01T19:00:00Z</news:publication_date>
        <news:title><![CDATA[After Decades of Damage and a Pandemic Spike, Where Does Alcohol-Associated Liver Disease Stand?]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/eadv-congress-2026-day-2-recap-6-headlines-to-know</loc><lastmod>2026-10-01T17:51:16.424Z</lastmod><news:news><news:publication_date>2026-10-01T17:51:16.424Z</news:publication_date>
        <news:title><![CDATA[EADV Congress 2026: Day 2 Recap—6 Headlines to Know]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/fda-approval-of-mavacamten-for-adolescents-addresses-massive-unmet-need</loc><lastmod>2026-10-01T17:00:00Z</lastmod><news:news><news:publication_date>2026-10-01T17:00:00Z</news:publication_date>
        <news:title><![CDATA[FDA Approval of Mavacamten for Adolescents Addresses Massive Unmet Need]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/fda-news-recap-novel-drug-approvals-in-q3-2026</loc><lastmod>2026-10-01T16:00:00Z</lastmod><news:news><news:publication_date>2026-10-01T16:00:00Z</news:publication_date>
        <news:title><![CDATA[FDA News Recap: Novel Drug Approvals in Q3 2026]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/nb-uvb-upadacitinib-higher-vitiligo-repigmentation-rates</loc><lastmod>2026-10-01T15:19:26.324Z</lastmod><news:news><news:publication_date>2026-10-01T15:19:26.324Z</news:publication_date>
        <news:title><![CDATA[NB-UVB Plus Upadacitinib Yields Higher Vitiligo Repigmentation Rates]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/nemolizumab-safety-real-world-use-in-ad-with-matthias-augustin-md</loc><lastmod>2026-10-01T14:30:57.450Z</lastmod><news:news><news:publication_date>2026-10-01T14:30:57.450Z</news:publication_date>
        <news:title><![CDATA[Nemolizumab Safety, Real-World Use in AD, With Matthias Augustin, MD]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/viaskin-peanut-patch-bla-submitted-peanut-allergy-children-4-7-years</loc><lastmod>2026-10-01T14:02:00Z</lastmod><news:news><news:publication_date>2026-10-01T14:02:00Z</news:publication_date>
        <news:title><![CDATA[Viaskin Peanut Patch BLA Submitted for Peanut Allergy in Children Aged 4-7 Years]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/nemolizumab-sustains-ad-response-at-3-years-with-matthias-augustin-md</loc><lastmod>2026-10-01T14:00:00Z</lastmod><news:news><news:publication_date>2026-10-01T14:00:00Z</news:publication_date>
        <news:title><![CDATA[Nemolizumab Sustains AD Response at 3 Years, With Matthias Augustin, MD]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/upadacitinib-feasible-palmoplantar-pustulosis-gleeson</loc><lastmod>2026-10-01T13:46:08.370Z</lastmod><news:news><news:publication_date>2026-10-01T13:46:08.370Z</news:publication_date>
        <news:title><![CDATA[Upadacitinib Feasible for Palmoplantar Pustulosis: David Gleeson, BM BCH]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/eadv-2026-tilrekimig-achieves-easi-75-across-all-doses-in-atopic-dermatitis</loc><lastmod>2026-10-01T11:49:56.728Z</lastmod><news:news><news:publication_date>2026-10-01T11:49:56.728Z</news:publication_date>
        <news:title><![CDATA[EADV 2026: Tilrekimig Achieves EASI-75 Across All Doses in Atopic Dermatitis]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/nail-detachment-4-times-more-common-with-glp-1-use</loc><lastmod>2026-10-01T10:57:05.062Z</lastmod><news:news><news:publication_date>2026-10-01T10:57:05.062Z</news:publication_date>
        <news:title><![CDATA[Nail Detachment 4 Times More Common With GLP-1 Use]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/be-heard-ext-bimekizumab-shows-improved-hs-effects-earlier-use</loc><lastmod>2026-10-01T09:46:02.447Z</lastmod><news:news><news:publication_date>2026-10-01T09:46:02.447Z</news:publication_date>
        <news:title><![CDATA[BE HEARD EXT: Bimekizumab Shows Improved HS Effects with Earlier Use]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/tips-recognizing-hidradenitis-suppurativa-skin-color-julia-riley-md</loc><lastmod>2026-10-01T08:58:14.405Z</lastmod><news:news><news:publication_date>2026-10-01T08:58:14.405Z</news:publication_date>
        <news:title><![CDATA[Tips for Recognizing Hidradenitis Suppurativa in Skin of Color, With Julia Riley, MD]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/easd-2026-eloratzp-bests-tirzepatide-on-weight-loss-a1c-in-type-2-diabetes</loc><lastmod>2026-09-30T22:27:40.355Z</lastmod><news:news><news:publication_date>2026-09-30T22:27:40.355Z</news:publication_date>
        <news:title><![CDATA[EASD 2026: EloraTZP Bests Tirzepatide on Weight Loss, A1C in Type 2 Diabetes]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/fda-approves-mavacamten-for-pediatric-patients-with-obstructive-hcm</loc><lastmod>2026-09-30T22:00:00Z</lastmod><news:news><news:publication_date>2026-09-30T22:00:00Z</news:publication_date>
        <news:title><![CDATA[FDA Approves Mavacamten for Pediatric Patients With Obstructive HCM]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/us-alcohol-use-falls-but-not-for-adults-aged-50-to-64-with-brian-lee-md</loc><lastmod>2026-09-30T19:13:05.983Z</lastmod><news:news><news:publication_date>2026-09-30T19:13:05.983Z</news:publication_date>
        <news:title><![CDATA[US Alcohol Use Falls, but Not for Adults Aged 50 to 64, With Brian Lee, MD]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/proteinuria-response-in-fibrillary-gn-what-defines-a-non-responder</loc><lastmod>2026-09-30T19:00:00Z</lastmod><news:news><news:publication_date>2026-09-30T19:00:00Z</news:publication_date>
        <news:title><![CDATA[Proteinuria Response in Fibrillary GN: What Defines a Non-Responder]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/cardiovascular-disease-still-top-cause-of-us-mortality-despite-recent-advancements</loc><lastmod>2026-09-30T19:00:00Z</lastmod><news:news><news:publication_date>2026-09-30T19:00:00Z</news:publication_date>
        <news:title><![CDATA[Cardiovascular Disease Still Top Cause of US Mortality Despite Recent Advancements]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/fibrillary-glomerulonephritis-in-2026-why-treatment-remains-a-challenge</loc><lastmod>2026-09-30T18:16:00Z</lastmod><news:news><news:publication_date>2026-09-30T18:16:00Z</news:publication_date>
        <news:title><![CDATA[Fibrillary Glomerulonephritis in 2026: Why Treatment Remains a Challenge]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/eadv-congress-2026-day-1-recap-6-headlines-to-know</loc><lastmod>2026-09-30T17:56:05.789Z</lastmod><news:news><news:publication_date>2026-09-30T17:56:05.789Z</news:publication_date>
        <news:title><![CDATA[EADV Congress 2026: Day 1 Recap — 6 Headlines to Know]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/denifanstat-sustains-acne-control-52-weeks-bhatia</loc><lastmod>2026-09-30T16:06:55.389Z</lastmod><news:news><news:publication_date>2026-09-30T16:06:55.389Z</news:publication_date>
        <news:title><![CDATA[Denifanstat Sustains Acne Control Through 52 Weeks, With Neal Bhatia, MD]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/tulisokibart-phase-2b-efficacy-moderate-severe-hs</loc><lastmod>2026-09-30T15:21:36.076Z</lastmod><news:news><news:publication_date>2026-09-30T15:21:36.076Z</news:publication_date>
        <news:title><![CDATA[Tulisokibart Shows Phase 2b Efficacy in Moderate to Severe HS]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/q4-2026-preview-7-fda-decisions-to-watch</loc><lastmod>2026-09-30T15:00:00Z</lastmod><news:news><news:publication_date>2026-09-30T15:00:00Z</news:publication_date>
        <news:title><![CDATA[Q4 2026 Preview: 7 FDA Decisions to Watch]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/intralesional-bo-112-attains-61-response-basal-cell-carcinoma</loc><lastmod>2026-09-30T13:00:00Z</lastmod><news:news><news:publication_date>2026-09-30T13:00:00Z</news:publication_date>
        <news:title><![CDATA[Intralesional BO-112 Attains 61% Response in Basal Cell Carcinoma]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/eadv-2026-zasocitinib-tops-deucravacitinib-for-pasi-100-in-plaque-psoriasis</loc><lastmod>2026-09-30T12:27:21.028Z</lastmod><news:news><news:publication_date>2026-09-30T12:27:21.028Z</news:publication_date>
        <news:title><![CDATA[EADV 2026: Zasocitinib Tops Deucravacitinib for PASI 100 in Plaque Psoriasis]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/climate-change-skin-disease-worsening-42-of-countries</loc><lastmod>2026-09-30T11:55:47.018Z</lastmod><news:news><news:publication_date>2026-09-30T11:55:47.018Z</news:publication_date>
        <news:title><![CDATA[Climate Change Tied to Skin Disease Worsening in 42% of Countries]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/apex-part-b-zumilokibart-achieves-primary-endpoint-atopic-dermatitis</loc><lastmod>2026-09-30T07:16:09.123Z</lastmod><news:news><news:publication_date>2026-09-30T07:16:09.123Z</news:publication_date>
        <news:title><![CDATA[APEX Part B: Zumilokibart Achieves Primary Endpoint in Atopic Dermatitis]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/cupid-a-c-dupilumab-improves-quality-life-omalizumab-naive-csu</loc><lastmod>2026-09-30T05:00:00Z</lastmod><news:news><news:publication_date>2026-09-30T05:00:00Z</news:publication_date>
        <news:title><![CDATA[CUPID A and C: Dupilumab Improves Quality of Life in Omalizumab-Naive CSU]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/retatrutide-improves-weight-loss-knee-osteoarthritis-pain-sleep-apnea-versus-placebo</loc><lastmod>2026-09-29T23:00:00Z</lastmod><news:news><news:publication_date>2026-09-29T23:00:00Z</news:publication_date>
        <news:title><![CDATA[Retatrutide Improves Weight Loss, Knee Osteoarthritis Pain, Sleep Apnea Versus Placebo]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/navigating-corticosteroid-stewardship-in-dermatology-with-kristina-derrick-md</loc><lastmod>2026-09-29T19:00:00Z</lastmod><news:news><news:publication_date>2026-09-29T19:00:00Z</news:publication_date>
        <news:title><![CDATA[Navigating Corticosteroid Stewardship in Dermatology, With Kristina Derrick, MD]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/atacicept-slows-igan-decline-to-physiologic-rate-with-sayna-norouzi-md</loc><lastmod>2026-09-29T17:02:23.519Z</lastmod><news:news><news:publication_date>2026-09-29T17:02:23.519Z</news:publication_date>
        <news:title><![CDATA[Atacicept Slows IgAN Decline to Physiologic Rate, With Sayna Norouzi, MD]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/heart-failure-society-of-america-2026-preview-6-trials-to-watch</loc><lastmod>2026-09-29T16:30:00Z</lastmod><news:news><news:publication_date>2026-09-29T16:30:00Z</news:publication_date>
        <news:title><![CDATA[Heart Failure Society of America 2026 Preview: 6 Trials to Watch]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/exocrine-pancreatic-insufficiency-estimated-in-40-of-chronic-pancreatitis</loc><lastmod>2026-09-29T14:00:54.616Z</lastmod><news:news><news:publication_date>2026-09-29T14:00:54.616Z</news:publication_date>
        <news:title><![CDATA[Exocrine Pancreatic Insufficiency Estimated in 40% of Chronic Pancreatitis]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/coordinating-multidisciplinary-care-in-achondroplasia</loc><lastmod>2026-09-29T13:19:46.267Z</lastmod><news:news><news:publication_date>2026-09-29T13:19:46.267Z</news:publication_date>
        <news:title><![CDATA[Coordinating Multidisciplinary Care in Achondroplasia]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/supporting-health-independence-and-community-in-achondroplasia</loc><lastmod>2026-09-29T13:10:22.433Z</lastmod><news:news><news:publication_date>2026-09-29T13:10:22.433Z</news:publication_date>
        <news:title><![CDATA[Supporting Health, Independence, and Community in Achondroplasia]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/monitoring-treatment-response-and-adapting-care-in-achondroplasia</loc><lastmod>2026-09-29T13:09:03.160Z</lastmod><news:news><news:publication_date>2026-09-29T13:09:03.160Z</news:publication_date>
        <news:title><![CDATA[Monitoring Treatment Response and Adapting Care in Achondroplasia]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/emerging-fgfr3-targeted-therapies</loc><lastmod>2026-09-29T13:08:03.232Z</lastmod><news:news><news:publication_date>2026-09-29T13:08:03.232Z</news:publication_date>
        <news:title><![CDATA[Emerging FGFR3-Targeted Therapies]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/evaluating-long-acting-cnp-therapy-in-achondroplasia</loc><lastmod>2026-09-29T13:07:09.952Z</lastmod><news:news><news:publication_date>2026-09-29T13:07:09.952Z</news:publication_date>
        <news:title><![CDATA[Evaluating Long-Acting CNP Therapy in Achondroplasia]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/long-term-outcomes-with-cnp-analogue-therapy-in-achondroplasia</loc><lastmod>2026-09-29T13:06:02.583Z</lastmod><news:news><news:publication_date>2026-09-29T13:06:02.583Z</news:publication_date>
        <news:title><![CDATA[Long-Term Outcomes With CNP Analogue Therapy in Achondroplasia]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/deciding-when-to-start-treatment-in-achondroplasia</loc><lastmod>2026-09-29T13:04:06.948Z</lastmod><news:news><news:publication_date>2026-09-29T13:04:06.948Z</news:publication_date>
        <news:title><![CDATA[Deciding When to Start Treatment in Achondroplasia]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/semaglutide-2-mg-escalation-tied-to-lower-mace-vs-tirzepatide-switch-in-t2d</loc><lastmod>2026-09-29T11:23:11.637Z</lastmod><news:news><news:publication_date>2026-09-29T11:23:11.637Z</news:publication_date>
        <news:title><![CDATA[Semaglutide 2 mg Escalation Tied to Lower MACE vs Tirzepatide Switch in T2D]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/lipoprotein-a-consistently-linked-to-incident-venous-thromboembolism-in-new-study</loc><lastmod>2026-09-28T23:00:00Z</lastmod><news:news><news:publication_date>2026-09-28T23:00:00Z</news:publication_date>
        <news:title><![CDATA[Lipoprotein(a) Consistently Linked to Incident Venous Thromboembolism in New Study]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/ochsner-health-expands-liver-transplant-access-through-multidisciplinary-care</loc><lastmod>2026-09-28T21:01:04.049Z</lastmod><news:news><news:publication_date>2026-09-28T21:01:04.049Z</news:publication_date>
        <news:title><![CDATA[Ochsner Health Expands Liver Transplant Access Through Multidisciplinary Care]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/q-a-cutlip-on-the-selution-slr-deb-s-fda-approval-for-coronary-in-stent-restenosis</loc><lastmod>2026-09-28T19:00:00Z</lastmod><news:news><news:publication_date>2026-09-28T19:00:00Z</news:publication_date>
        <news:title><![CDATA[Q&A: Cutlip on the SELUTION SLR DEB’s FDA Approval for Coronary In-Stent Restenosis]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/lessons-from-10-000-organ-transplants-with-ari-cohen-md</loc><lastmod>2026-09-28T16:24:37.709Z</lastmod><news:news><news:publication_date>2026-09-28T16:24:37.709Z</news:publication_date>
        <news:title><![CDATA[Lessons From 10,000 Organ Transplants, With Ari Cohen, MD]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/brelovitug-meets-primary-endpoint-phase-3-azure-1-hepatitis-delta-trial</loc><lastmod>2026-09-28T15:22:26.820Z</lastmod><news:news><news:publication_date>2026-09-28T15:22:26.820Z</news:publication_date>
        <news:title><![CDATA[Brelovitug Meets Primary Endpoint in Phase 3 AZURE-1 Hepatitis Delta Trial]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/reimbursement-coverage-care-gaps-patients-skin-of-color</loc><lastmod>2026-09-28T14:00:00Z</lastmod><news:news><news:publication_date>2026-09-28T14:00:00Z</news:publication_date>
        <news:title><![CDATA[Skin of Color Savvy: Reimbursement, Coverage, and Care Gaps for Patients With Skin of Color]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/monitoring-disease-control-in-eoe</loc><lastmod>2026-09-28T12:05:00Z</lastmod><news:news><news:publication_date>2026-09-28T12:05:00Z</news:publication_date>
        <news:title><![CDATA[Monitoring Disease Control in EoE]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url></urlset>